Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is a direct-acting, reversible P2Y12 platelet inhibitor.
## Primary Indications
* Reduction of thrombotic cardiovascular events (e.g., myocardial infarction, stroke) in patients with acute coronary syndrome (ACS) or a history of myocardial infarction.
## Adult Dosing
* **ACS:** 180 mg orally once, then 90 mg orally twice daily for at least 12 months, or as clinically indicated.
* **Post-MI (if history of MI and other indications):** 90 mg orally twice daily.
* **Combination Therapy:** Typically used in combination with aspirin. Lowest effective dose of aspirin (e.g., 75-100 mg daily) is recommended for patients with ACS. For secondary prevention post-MI, aspirin may be continued indefinitely.
## Pediatric Dosing
* Dosing in pediatric patients is not established.
## Dose Adjustments
* **Hepatic Impairment:** No dose adjustment is necessary in patients with mild to moderate hepatic impairment. Use with caution in severe hepatic impairment.
* **Renal Impairment:** No dose adjustment is necessary in patients with mild to moderate renal impairment. Limited data in severe renal impairment; use with caution.
## Contraindications
* History of intracerebral hemorrhage.
* Active bleeding.
* Known hypersensitivity to ticagrelor or any of its excipients.
## Adverse Effects
* **Common:** Dyspnea, bruising, bleeding (including fatal and serious cases, primarily gastrointestinal and intracerebral).
* **Less Common:** Ventricular pauses, hyperuricemia, cutaneous reactions.
## Key Drug Interactions
* **CYP3A4 Substrates:** Ticagrelor is a moderate inhibitor of CYP3A4. Concomitant use with strong CYP3A4 inhibitors may increase ticagrelor exposure.
* **CYP3A4 Inducers:** Concomitant use with strong CYP3A4 inducers (e.g., rifampin, phenytoin, carbamazepine, St. John's wort) may decrease ticagrelor exposure.
* **Aspirin:** Combination therapy with aspirin is common but increases bleeding risk.
* **Other Antithrombotics:** Concomitant use with other antithrombotic agents (e.g., warfarin, other antiplatelets, NSAIDs) increases bleeding risk.
* **Digoxin:** Ticagrelor may increase digoxin concentrations. Monitor digoxin levels and for signs of digoxin toxicity.
## Monitoring
* **Bleeding:** Closely monitor for signs and symptoms of bleeding, especially during initial treatment and after dose adjustments or concomitant therapy changes.
* **Ventricular Pauses:** ECG monitoring may be considered, particularly in patients with risk factors for bradycardia.
## Clinical Pearls
* Ticagrelor is a reversible P2Y12 inhibitor, meaning platelet function can be restored more quickly compared to irreversible inhibitors upon discontinuation, which may be advantageous in situations requiring urgent surgery.
* Dyspnea is a common side effect and may not be related to cardiac or pulmonary disease. If persistent or severe, consider dose reduction or discontinuation.
* Discontinuation of ticagrelor before cessation of aspirin may increase the risk of thrombotic events.
* Consider the duration of therapy based on individual patient risk and benefit, especially in ACS patients.
***
*Disclaimer: This information is intended for healthcare professionals. Always consult the official prescribing information and relevant guidelines for complete details and to confirm current recommendations before making any clinical decisions.*
